REG - Yourgene Health PLC - Director/PDMR Shareholding
RNS Number : 8969ZYourgene Health PLC23 September 2020
Yourgene Health plc
("Yourgene" or the "Company")
Director/PDMR Shareholding
Manchester, UK - 23 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it was notified today of the following director share purchases.
The following directors have made the following share purchases on 23 September 2020:
Director
Purchase price
Number of shares purchased
Total number of shares owned following purchase
Percentage of issued share capital held following purchase
Dr John Brown
18 pence
150,000
250,000
0.03%
Hayden Jeffreys
18 pence
27,634
333,494
0.05%
Barry Hextall
18 pence
27,626
549,675
0.08%
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Yourgene Health plc
Lyn Rees, Chief Executive Officer
Tel: +44 (0)161 669 8122
investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD)
Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico Lazzaretti
N+1 Singer (Joint Corporate Broker)
Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George Tzimas
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
Tel: +44 (0)20 7710 7600
Nicholas Moore / Matthew Blawat / Ben Maddison
Walbrook PR Ltd (Media and Investor Relations)
Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Paul McManus / Lianne Cawthorne
Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and molecular genetics. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.
Yourgene is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
a) Dr John Brown
b) Hayden Jeffreys
c) Barry Hextall
2
Reason for notification
a.
Position/Status
a) Senior Independent Director
b) Chief Operating Officer
c) Chief Financial Officer
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Yourgene Health plc
b.
LEI
213800UUIT8BZE7QEH33
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification CodeOrdinary shares of 0.1p each
ISIN: GB00BN31ZD89
b.
Nature of the transaction
Purchase
c.
Price(s) and volume(s)
Price(s)
Volume(s)
a) 18p
b) 18p
c) 18p
a) 150,000
b) 27,634
c) 27,626
e.
Date of the transaction
23 September 2020
f.
Place of the transaction
UK
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHFXLFLBKLLBBX
Recent news on Yourgene Health
See all newsREG - Velay Financial - Form 8.3 - YOURGENE HEALTH PLC
AnnouncementREG - AIM Yourgene Health PLC - Cancellation - Yourgene Health plc
AnnouncementREG - Yourgene Health PLC - De-listing and cancellation of trading of Shares
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
Announcement